# STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

> **NCT01653067** · PHASE2 · UNKNOWN · sponsor: **Mathias Witzens-Harig** · enrollment: 88 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Rituximab, Temsirolimus, DHAP, intravenous

## Key facts

- **NCT ID:** NCT01653067
- **Lead sponsor:** Mathias Witzens-Harig
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2018-06
- **Final completion:** 2018-07
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2016-10-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01653067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01653067, "STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01653067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*